Xenetic Biosciences Inc. (XBIO)
Xenetic Biosciences Statistics
Share Statistics
Xenetic Biosciences has 1.54M shares outstanding. The number of shares has increased by 0.09% in one year.
| Shares Outstanding | 1.54M |
| Shares Change (YoY) | 0.09% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 3.8% |
| Shares Floating | 1.25M |
| Failed to Deliver (FTD) Shares | 38 |
| FTD / Avg. Volume | 0.6% |
Short Selling Information
The latest short interest is 14.83K, so 0.96% of the outstanding shares have been sold short.
| Short Interest | 14.83K |
| Short % of Shares Out | 0.96% |
| Short % of Float | 1.18% |
| Short Ratio (days to cover) | 0.77 |
Valuation Ratios
The PE ratio is -1.55 and the forward PE ratio is -6.21. Xenetic Biosciences's PEG ratio is 0.3.
| PE Ratio | -1.55 |
| Forward PE | -6.21 |
| PS Ratio | 2.46 |
| Forward PS | 0.4 |
| PB Ratio | 1.02 |
| P/FCF Ratio | -2.18 |
| PEG Ratio | 0.3 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Xenetic Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.37, with a Debt / Equity ratio of 0.
| Current Ratio | 7.37 |
| Quick Ratio | 7.37 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.25M |
| Profits Per Employee | $-1.98M |
| Employee Count | 2 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -41.14% in the last 52 weeks. The beta is 2.18, so Xenetic Biosciences's price volatility has been higher than the market average.
| Beta | 2.18 |
| 52-Week Price Change | -41.14% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 3.95 |
| Relative Strength Index (RSI) | 26.29 |
| Average Volume (20 Days) | 6.34K |
Income Statement
In the last 12 months, Xenetic Biosciences had revenue of 2.5M and earned -3.96M in profits. Earnings per share was -2.57.
| Revenue | 2.5M |
| Gross Profit | 2.5M |
| Operating Income | -4.2M |
| Net Income | -3.96M |
| EBITDA | -4.2M |
| EBIT | -4.2M |
| Earnings Per Share (EPS) | -2.57 |
Balance Sheet
The company has 6.17M in cash and 0 in debt, giving a net cash position of 6.17M.
| Cash & Cash Equivalents | 6.17M |
| Total Debt | 0 |
| Net Cash | 6.17M |
| Retained Earnings | -197.19M |
| Total Assets | 6.9M |
| Working Capital | 5.69M |
Cash Flow
In the last 12 months, operating cash flow was -2.82M and capital expenditures 0, giving a free cash flow of -2.82M.
| Operating Cash Flow | -2.82M |
| Capital Expenditures | 0 |
| Free Cash Flow | -2.82M |
| FCF Per Share | -1.83 |
Margins
Gross margin is 100%, with operating and profit margins of -168.16% and -158.39%.
| Gross Margin | 100% |
| Operating Margin | -168.16% |
| Pretax Margin | -158.39% |
| Profit Margin | -158.39% |
| EBITDA Margin | -168.16% |
| EBIT Margin | -168.16% |
| FCF Margin | -112.69% |
Dividends & Yields
XBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for XBIO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 15, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | May 15, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -38.11 |
| Piotroski F-Score | 2 |